Trial Profile
A Retrospective study of Crizotinib in advanced Non-Small Cell Lung Cancer with ALK/ROS-1 mutations
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jun 2018
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 21 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology